Pharmacodynamic Approaches to Optimizing Beta-Lactam Therapy

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 77-93

  Crandon, Jared L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Beta lactam; Continuous infusion; Pharmacodynamics; Prolonged infusion

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; DORIPENEM; IMIPENEM; MEROPENEM; NAFCILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BACTEREMIA; COST BENEFIT ANALYSIS; CREATININE CLEARANCE; FEBRILE NEUTROPENIA; HOSPITAL INFECTION; HUMAN; IMMUNE STATUS; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOCYTOSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OBESITY; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SEPSIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHILD; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; THIENAMYCINS; TIME FACTORS;

EID: 78649952845     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.004     Document Type: Review

References (65)

1. America ATSatIDSo Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
2. Solomkin J.S., Mazuski J.E., Bradley J.S., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010, 11:79-109.
3. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
4. Eagle H., Fleischman R., Levy M. " Continuous" vs. " discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med 1953, 248:481-488.
5. Eagle H., Fleischman R., Musselman A.D. Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950, 9:280-299.
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. [quiz: 11-2].
7. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27:10-22.
8. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36:S42-S50.
9. Li C., Du X., Kuti J.L., et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730.
10. Crandon J.L., Bulik C.C., Kuti J.L., et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:1111-1116.
11. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996, 15:255-259.
12. Nicolau D.P., Sutherland C.A., Arguedas A., et al. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media. Paediatr Drugs 2007, 9:119-123.
13. Nicolau D.P. Optimizing antimicrobial therapy and emerging pathogens. Am J Manag Care 1998, 4:S525-S530.
14. Lodise T.P., Lomaestro B., Rodvold K.A., et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004, 48:4718-4724.
15. Kim A., Sutherland C.A., Kuti J.L., et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?. Pharmacotherapy 2007, 27:1490-1497.
16. Nicasio A.M., Ariano R.E., Zelenitsky S.A., et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53:1476-1481.
17. Koomanachai P., Bulik C.C., Kuti J.L., et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010, 32:766-779.
18. Bulik C.C., Fauntleroy K.A., Jenkins S.G., et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010, 48:2402-2406.
19. Torres E., Villanueva R., Bou G. Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa. J Med Microbiol 2009, 58:625-629.
20. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2009, 25:69-77.
21. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
22. Kim A., Banevicius M.A., Nicolau D.P. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008, 52:2497-2502.
23. Crandon J.L., Bulik C.C., Nicolau D.P. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009, 53:4352-4356.
24. Bhavnani S.M., Hammel J.P., Cirincione B.B., et al. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005, 49:3944-3947.
25. Van Wart S.A., Andes D.R., Ambrose P.G., et al. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009, 63:409-414.
26. Roosendaal R., Bakker-Woudenberg I.A., van den Berg J.C., et al. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985, 152:373-378.
27. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., et al. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986, 30:403-408.
28. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., et al. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989, 8:878-887.
29. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., et al. Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. Pharm Weekbl Sci 1987, (Suppl 9):S33-S40.
30. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., et al. Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 1987, 31:1809-1815.
31. Croisier D., Martha B., Piroth L., et al. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. Int J Antimicrob Agents 2008, 32:494-498.
32. Kuti J.L., Maglio D., Nightingale C.H., et al. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2003, 60:565-568.
33. Arnold H.M., McKinnon P.S., Augustin K.M., et al. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Pharmacotherapy 2009, 29:914-923.
34. Kotapati S., Nicolau D.P., Nightingale C.H., et al. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2004, 61:1264-1270.
35. Patel G.W., Duquaine S.M., McKinnon P.S. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. Pharmacotherapy 2007, 27:1637-1643.
36. Lodise T.P., Lomaestro B.M., Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26:1320-1332.
37. Bulik C.C., Quintiliani R., Samuel Pope J., et al. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis - A review of 3 cases. Respir Med CME October 14, 2009, online.
38. Kuti J.L., Moss K.M., Nicolau D.P., et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004, 24:1641-1645.
39. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
40. Hanes S.D., Wood G.C., Herring V., et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179:436-440.
41. Nicolau D.P., McNabb J., Lacy M.K., et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17:497-504.
42. Georges B., Conil J.M., Cougot P., et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43:360-369.
43. Roberts J.A., Boots R., Rickard C.M., et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007, 59:285-291.
44. Lau W.K., Mercer D., Itani K.M., et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50:3556-3561.
45. Bodey G.P., Ketchel S.J., Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979, 67:608-616.
46. Moriyama B., Henning S.A., Childs R., et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010, 44:929-935.
47. Grant E.M., Zhong M.K., Ambrose P.G., et al. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health Syst Pharm 2000, 57:992-995.
48. Anon J.B., Jacobs M.R., Poole M.D., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004, 130:1-45.
49. Dandekar P.K., Nicolau D.P. Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis. Otolaryngol Head Neck Surg 2002, 127:S10-S16.
50. Fallon R.M., Kuti J.L., Doern G.V., et al. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs 2008, 10:329-335.
51. Pichichero M.E., Doern G.V., Kuti J.L., et al. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatr Drugs 2008, 10:391-397.
52. Society of Critical Care Medicine's 39th Critical Care Congress 2010 [abstract 832]. Miami (FL), January 9-13, 2010.
53. Patel N., Scheetz M.H., Drusano G.L., et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010, 54:460-465.
54. Diekema D.J., Pfaller M.A., Jones R.N. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. Int J Antimicrob Agents 2002, 20:412-418.
55. Jones R.N., Biedenbach D.J., Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003, 46:77-80.
56. Courter J.D., Kuti J.L., Girotto J.E., et al. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009, 53:379-385.
57. Ellis J.M., Kuti J.L., Nicolau D.P. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther 2005, 27:1820-1830.
58. Grant E.M., Kuti J.L., Nicolau D.P., et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002, 22:471-483.
59. McNabb J.J., Nightingale C.H., Quintiliani R., et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001, 21:549-555.
60. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
61. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420.
62. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
63. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:196-200.
64. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785.
65. Nicasio A.M., Eagye K.J., Kuti E.L., et al. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010, 30:453-462.